However, results from these studies demonstrate an overall trend towards improved outcomes within biomarker-selected populations, highlighting the importance of biomarker-driven patient selection for future trials.
← all excerpts
Targeted therapies in hepatocellular carcinoma: past, present, and future.
1
—
—